Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Glutamate receptor 4 (GluA4), encoded by the GRIA4 gene, is a subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which is a ligand-gated ion channel responsible for the majority of fast excitatory neurotransmission in the central nervous system (UniProt P48058). GluA4 is particularly significant during early brain development, where it facilitates the maturation of excitatory synapses and the conversion of silent synapses into functional ones (PubMed: 22114271). In the adult brain, GluA4-containing receptors are characterized by rapid activation and desensitization kinetics, playing specialized roles in high-frequency signaling within circuits like the thalamus and cerebellum. Genetic variations or dysregulation of GluA4 are associated with neurodevelopmental disorders, intellectual disability, and various forms of epilepsy, including absence seizures (NCBI Gene: 2893). Pharmacologically, this subunit is a target for non-competitive antagonists such as perampanel, which are used clinically to manage seizures by dampening overactive glutamatergic signaling (PubMed: 22569160). Additionally, positive allosteric modulators (AMPAkines) are being researched for their potential to improve cognitive deficits in neuropsychiatric conditions by enhancing the duration of the receptor's open state.
Non-competitive antagonism of the AMPA receptor complex; positive allosteric modulation of receptor kinetics.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor 4 (GluA4) (GRIA4).